{'fraction_non_alphanumeric': 0.03569023569023569, 'fraction_numerical': 0.01818181818181818, 'mean_word_length': 5.489082969432315, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Formulation of new intelligent nanoparticle inhibited H1N1 influenza subtype and SARS coronavirus type 2 (COVID-19) in vitro

Background: Rapid infection of the coronavirus and frequency of the subtypes are the main problems of drug and vaccine intervention during COVID-19 pandemic. New drug discovery to respond these needs, is the goal of study. Hence, considering structural and biological components of SARS-CoV-2, new intelligent particle designed and formulated and several dockings were done as in silico assay. Methods: Fe3O4 nanoparticles synthesized by the coprecipitation method, coated and functionalized. Chemical bindings (Fourier transform infrared assay), magnetic behavior (vibrating sample magnetometer assay), morphology (field emission scanning electron microscope assay), and cell toxicity and cell viability (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay) were checked and confirmed in vitro by exposure of particles to the H1N1 virus laboratory media exposure (BSL2 category). Results: Results show drug has ability to reduce more than 4 logarithms in the virus titration, in concentration of 70 μg/ml, so it was proved these nanoparticles could have antiviral effect. Although, because of lack of BSL3 standard laboratory, the antiviral effect on COVID-19 could not be performed on large scale. Conclusions: By the way, we concluded that new specific nanoparticles could make a new chance for COVID-19 drug therapy at any subtype exposure.